EyePoint Pharmaceuticals Inc.

11.72+0.5100+4.55%Vol 188.97K1Y Perf 116.58%
Sep 24th, 2021 16:00 DELAYED
BID11.65 ASK11.72
Open11.25 Previous Close11.21
Pre-Market- After-Market-
 - -  - -%
Target Price
20.67 
Analyst Rating
Moderate Buy 2.33
Potential %
76.37 
Finscreener Ranking
★★★★+     58.23
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     53.75
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     59.62
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
71.08 
Earnings Rating
Sell
Market Cap337.18M 
Earnings Date
4th Nov 2021
Alpha-0.01 Standard Deviation0.25
Beta1.29 

Today's Price Range

11.1512.20

52W Range

3.5115.06

5 Year PE Ratio Range

-2.20-2.00

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
6.16%
1 Month
17.55%
3 Months
23.11%
6 Months
13.35%
1 Year
116.58%
3 Years
-62.44%
5 Years
-63.60%
10 Years
-71.62%

TickerPriceChg.Chg.%
EYPT11.720.51004.55
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Financial StrengthValueIndustryS&P 500US Markets
8.80
9.30
0.26
0.36
-5.50
Leverage Ratio 2.10
ProfitabilityValueIndustryS&P 500US Markets
80.40
-89.80
-82.90
-
-
RevenueValueIndustryS&P 500US Markets
39.16M
1.36
123.25
76.68
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.45-0.3522.22
Q01 2021-0.53-0.505.66
Q04 20200.45-1.01-324.44
Q03 2020-0.10-0.30-200.00
Q02 2020-1.10-1.009.09
Q01 2020-1.00-1.10-10.00
Q04 2019-1.20-0.9025.00
Q03 2019-1.40-1.400.00
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.47-9.30Negative
12/2021 QR-0.47-14.63Negative
12/2021 FY-1.696.11Positive
12/2022 FY-1.86-29.17Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.47
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume188.97K
Shares Outstanding28.77M
Shares Float21.42M
Trades Count2.42K
Dollar Volume3.02M
Avg. Volume240.60K
Avg. Weekly Volume137.54K
Avg. Monthly Volume110.02K
Avg. Quarterly Volume170.82K

EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) stock closed at 11.72 per share at the end of the most recent trading day (a 4.55% change compared to the prior day closing price) with a volume of 189.11K shares and market capitalization of 337.18M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 84 people. EyePoint Pharmaceuticals Inc. CEO is Nancy Lurker.

The one-year performance of EyePoint Pharmaceuticals Inc. stock is 116.58%, while year-to-date (YTD) performance is 78.12%. EYPT stock has a five-year performance of -63.6%. Its 52-week range is between 3.51 and 15.06, which gives EYPT stock a 52-week price range ratio of 71.08%

EyePoint Pharmaceuticals Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 2.97, a price-to-sale (PS) ratio of 7.79, a price to cashflow ratio of 10.50, a PEG ratio of 2.32, a ROA of -32.94%, a ROC of -35.06% and a ROE of -74.69%. The company’s profit margin is -%, its EBITDA margin is -82.90%, and its revenue ttm is $39.16 Million , which makes it $1.36 revenue per share.

Of the last four earnings reports from EyePoint Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.47 for the next earnings report. EyePoint Pharmaceuticals Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for EyePoint Pharmaceuticals Inc. is Moderate Buy (2.33), with a target price of $20.67, which is +76.37% compared to the current price. The earnings rating for EyePoint Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

EyePoint Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

EyePoint Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.24, ATR14 : 0.59, CCI20 : 201.15, Chaikin Money Flow : 0.06, MACD : 0.34, Money Flow Index : 51.47, ROC : 11.51, RSI : 68.65, STOCH (14,3) : 81.82, STOCH RSI : 1.00, UO : 64.27, Williams %R : -18.18), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of EyePoint Pharmaceuticals Inc. in the last 12-months were: Dario A. Paggiarino (Option Excercise at a value of $0), David R. Guyer (Option Excercise at a value of $0), David Scott Jones (Option Excercise at a value of $0), Douglas E. Godshall (Option Excercise at a value of $0), Goran A. Ando (Option Excercise at a value of $0), John B. Landis (Option Excercise at a value of $0), Nancy Lurker (Option Excercise at a value of $0), Nancy S. Lurker (Option Excercise at a value of $0), Wendy F. DiCicco (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Moderate Buy
1.67

EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed 5 FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.

CEO: Nancy Lurker

Telephone: +1 617 926-5000

Address: 480 Pleasant Street, Watertown 02472, MA, US

Number of employees: 84

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

53%47%

Bearish Bullish

63%38%

TipRanks News for EYPT

News

Stocktwits